Cadila Healthcare jumps on the BSE
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Cadila Healthcare is currently trading at Rs. 579.00, up by 7.80 points or 1.37% from its previous closing of Rs. 571.20 on the BSE.
The scrip opened at Rs. 605.00 and has touched a high and low of Rs. 605.00 and Rs. 571.00 respectively. So far 1267433 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 605.00 on 26-Apr-2021 and a 52 week low of Rs. 318.10 on 08-May-2020.
Last one week high and low of the scrip stood at Rs. 605.00 and Rs. 513.65 respectively. The current market cap of the company is Rs. 59177.44 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.53% and 8.40% respectively.
Zydus Cadila has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
